Chronic lymphocytic leukemia (CLL) is a malignancy of well-differentiated CD5 + CD19 + monoclonal B cells; the incidence increases with age. There is a very broad spectrum of clinical course for CLL.

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.

Richter transformation develops in 2%–10% of CLL cases, often with rapid clinical decline, limited chemotherapy efficacy, and ...

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process. Lori A. Leslie, MD: Hello, and welcome to CURE Expert Connections® ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...

The most commonly used staging systems worldwide are Rai and Binet, since both are both simple, inexpensive, and easy to use. Staging systems cannot differentiate individuals who will have progressive ...

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Genetic predisposition and lifestyle factors both play crucial roles in diabetes management and onset. Cancer treatment can complicate diabetes management, requiring careful coordination between ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

CLL is the most common leukemia in adults in Western countries, with a male predominance and an average age at diagnosis of 72 years. The disease is characterized by an accumulation of monoclonal, ...